Cathie Wood's position in CRISPR Therapeutics AG is currently worth $630 Million. That's 3.77% of their equity portfolio (7th largest holding). The investor owns 12.48% of the outstanding CRISPR Therapeutics AG stock. The first CRISPR Therapeutics AG trade was made in Q2 2017. Since then Cathie Wood bought shares thirteen more times and sold shares on four occasions. The investor's estimated purchase price is $689 Million, resulting in a loss of 8.6%.